QT Vascular on why it chose to list in Singapore
QT Vascular, a company producing devices to treat diseased arteries in the heart and elsewhere, aims to develop new products and enhance its existing ones, and so is planning a listing on the Singapore Exchange (SGX) to fund its efforts.
The company, which operates out of California and Singapore, registered revenue of US$1,452,000 for FY2012; in FY2013 that ended Sept 30, revenue doubled to US$3,004,000.
Besides developing new products, the company plans to use the IPO proceeds for commercial expansion and for general working capital purposes.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Air China to buy 100 locally made C919 jets in US$11 billion deal
HCA beats first-quarter profit estimates on higher patient admissions
F&B operator YKGI to exclusively operate Chicha San Chen in Macau for next eight years
LMIRT Q1 net property income dips 3.1% to S$30 million on higher expenses
Exxon misses on Q1 profit despite big gains in Guyana
US FDA approves Pfizer’s gene therapy for rare bleeding disorder